Jennifer Kim, MD
Ophthalmology · Morrow, GANPI 1811286149
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 201 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 32 manufacturers reported payments, led by Alcon at 27.3% of the total.
Across 201 payments — averaging $39.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$2K
- Glaukos Corporation$1K
- Bausch & Lomb Americas Inc.$587
- Sight Sciences, Inc.$565
- Sun Pharmaceutical Industries Inc.$536
- Oyster Point Pharma, Inc.$382
- plus $3K from 26 others
Across 95 payments — averaging $10,332 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$421K
- Oyster Point Pharma, Inc.$231K
- Padagis US LLC$111K
- Glaukos Corporation$93K
- Bausch Health US, LLC$92K
- Amneal Pharmaceuticals LLC$34K
What the payments were for
- Travel & lodging$120%
- Food & beverage$7,812100%
- Gifts$190%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 55 | $2,141 |
| Glaukos Corporation | 26 | $1,001 |
| Bausch & Lomb Americas Inc. | 17 | $587 |
| Sight Sciences, Inc. | 11 | $565 |
| Sun Pharmaceutical Industries Inc. | 6 | $536 |
| Oyster Point Pharma, Inc. | 16 | $382 |
| AbbVie(2 entities) | 12 | $290 |
| Novartis | 10 | $283 |
| Genentech USA, Inc. | 2 | $245 |
| Kowa Research Institute, Inc. | 1 | $228 |
| Biotissue Holdings Inc. | 4 | $185 |
| Kala Pharmaceuticals, Inc. | 4 | $173 |
| Amgen(2 entities) | 3 | $166 |
| Harrow Eye, LLC | 5 | $144 |
| Rxsight Inc | 2 | $131 |
| Carl Zeiss Meditec USA, Inc. | 1 | $128 |
| Alimera Sciences, Inc. | 1 | $127 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 6 | $82 |
| Tarsus Pharmaceuticals, Inc. | 3 | $77 |
| NEW World Medical,inc. | 1 | $45 |
| Dompe US, Inc. | 2 | $40 |
| Thea Pharma Inc. | 2 | $39 |
| Grifols USA, LLC | 1 | $35 |
| Ortho-clinical Diagnostics, Inc. | 1 | $35 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $30 |
| Viiv Healthcare Company | 1 | $29 |
| Ocular Therapeutix, Inc. | 1 | $24 |
| Iridex Corporation | 1 | $21 |
| Shire North American Group Inc | 1 | $21 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Eyevance Pharmaceuticals LLC | 1 | $19 |
| Carl Zeiss Meditec, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Clareon$565
- Hydrus Microstent$408
- CEQUA$249
- VABYSMO$245
- OMNI(R) SURGICAL SYSTEM (US)$149
- TearCare SmartLid$146
- TEARCARE(TM) (2.2) SYSTEM KIT$146
- Prokera$144
- AmnioGraft$144
- ARGOS$141
- enVista MX60 IOL$138
- TEARCARE SYSTEM$131
- CLARUS$128
- Iluvien$127
- TEPEZZA$125
- VYZULTA$125
- TYRVAYA$125
- ILUMYA$124
- XIIDRA$118
- INVELTYS$117
How this compares
$7,844 in reported general payments places this provider in the 80th percentile of 481 ophthalmology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IlevroNepafenac | 207 | $76,685 |
| Lotemax SmLoteprednol Etabonate | 219 | $56,426 |
| ProlensaBromfenac Sodium | 93 | $32,624 |
| XiidraLifitegrast | 19 | $29,333 |
| BesivanceBesifloxacin Hcl | 107 | $24,013 |
| Bromfenac Sodium | 54 | $10,454 |
| Prednisolone Acetate | 147 | $3,910 |
| MoxifloxacinMoxifloxacin Hcl | 99 | $2,015 |
| Loteprednol Etabonate | 12 | $1,981 |
| Ketorolac Tromethamine | 91 | $1,176 |
| Ofloxacin | 37 | $394 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 20 | $298 |
| Timolol Maleate | 14 | $123 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm, Prolensa, Besivance, Loteprednol Etabonate | $82 | $115,044431 claims |
| NovartisIlevro | $283 | $76,685207 claims |
| Bausch & Lomb Americas Inc.Xiidra | $587 | $29,33319 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 481 ophthalmology providers in Georgia.
Other ophthalmology in Morrow
- Harvey DubinerMorrow$31K
- Gagan SawhneyAtlanta$582K
- Lawrence WoodardAtlanta$578K
- Stephanie VanderveldtAtlanta$384K
- Steven YehAtlanta$289K
- Jack ChapmanGainesville$244K
- Gregory LeeCumming$214K
- Puneet PandaMarietta$185K
- Jeffrey TranSuwanee$150K
- Evan SchoenbergAtlanta$130K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.